DCM
PDSB icon

DAFNA Capital Management’s PDS Biotechnology PDSB Stock Holding History

DAFNA Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-970
Closed -$182K – 77
2017
Q4 		$182K Hold
970
– – 0.1% 68
2017
Q3 		$208K Hold
970
– – 0.13% 65
2017
Q2 		$199K Buy
+970
New +$191K 0.14% 68
2016
Q2 		– Sell
-3,459
Closed -$633K – 102
2016
Q1 		$633K Buy
+3,459
New +$618K 0.55% 54

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAFNA Capital Management's PDSB Position: Q1 2018 in Review

DAFNA Capital Management sold out of PDS Biotechnology (PDSB) in Q1 2018, closing a stake of 970 shares — an estimated $182K sold.

DAFNA Capital Management first reported a position in PDSB in Q1 2016 and held it in 4 quarters. The position peaked at $633K in Q1 2016. 60 funds tracked by Wall St. Rank hold PDSB as of Q1 2018.

  • DAFNA Capital Management reported no remaining PDS Biotechnology position as of Q1 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 970 PDS Biotechnology shares in Q1 2018, an estimated $182K.
  • DAFNA Capital Management first reported a position in PDS Biotechnology in Q1 2016 and held it in 4 quarters.
  • DAFNA Capital Management's PDS Biotechnology position peaked at $633K in Q1 2016.
  • 60 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2018.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.